Getz Pharma Diabetes Subtypes Study at Chughtai Lab

Getz Pharma Diabetes Subtypes Study at Chughtai Lab

The Getz Pharma (Diabetes Subtypes Study) at Chughtai Lab represents a landmark collaborative clinical initiative aimed at revolutionizing diabetes management in Pakistan. Diabetes mellitus is a highly prevalent, multi-faceted metabolic disorder that poses a significant public health challenge across the country. Historically, diabetes has been broadly classified into two primary categories: Type 1 and Type 2 diabetes. However, contemporary clinical research and endocrinology practice have revealed that diabetes is far more heterogeneous than previously understood. This specialized study, conducted in collaboration with Getz Pharma and executed across the extensive diagnostic network of Chughtai Lab, utilizes advanced biochemical and immunological profiling to classify diabetic patients into precise clinical subtypes. By identifying these distinct subtypes, healthcare providers can transition from a one-size-fits-all treatment model to highly personalized, precision medicine strategies.

This comprehensive diagnostic study evaluates key physiological markers, including pancreatic beta-cell function, insulin resistance, autoimmune activity, and metabolic parameters. The primary objective is to categorize patients into newly defined clinical clusters, such as Severe Autoimmune Diabetes (SAID), Severe Insulin-Deficient Diabetes (SIDD), Severe Insulin-Resistant Diabetes (SIRD), Mild Obesity-Related Diabetes (MOD), and Mild Age-Related Diabetes (MARD). Understanding these specific subtypes allows clinicians to predict disease progression, assess the risk of diabetic complications (such as nephropathy, neuropathy, and retinopathy), and select the most effective pharmacological interventions early in the disease course. Chughtai Lab utilizes state-of-the-art automated laboratory technology to ensure the highest level of analytical sensitivity and specificity for every biomarker evaluated in this study.

Clinical Procedure: What to Expect

Patient Preparation

To ensure the clinical accuracy of the biochemical assays performed during the Getz Pharma (Diabetes Subtypes Study) at Chughtai Lab, patients must adhere strictly to the following preparation guidelines:

• Fasting Requirement: Patients must fast for a minimum of 8 to 12 hours prior to sample collection. Only plain water is permitted during this fasting period. Avoid tea, coffee, juices, sodas, and food.
• Medication Management: Patients should consult their referring physician regarding their daily diabetes medications. In many cases, oral hypoglycemic agents or insulin injections should be withheld on the morning of the test until the blood sample has been drawn, to prevent hypoglycemia and ensure accurate baseline glucose and insulin measurements.
• Avoid Alcohol and Tobacco: Consumption of alcohol and tobacco products should be avoided for at least 24 hours before the test, as they can alter metabolic markers and liver enzyme profiles.
• Physical Activity: Strenuous physical exercise should be avoided for 24 hours prior to the blood draw, as intense physical exertion can temporarily alter insulin sensitivity and blood glucose levels.
• Hydration: Adequate hydration with water is highly recommended, as it facilitates easier venous access and ensures stable blood volume for sample processing.

During the Procedure

The collection of specimens for the Getz Pharma (Diabetes Subtypes Study) at Chughtai Lab is performed by highly trained phlebotomists adhering to strict international safety and quality standards:

• Patient Identification and Verification: The phlebotomist will verify the patient’s identity, confirm compliance with fasting instructions, and record any current medications or relevant clinical history.
• Venipuncture Site Selection: The patient will be seated comfortably. The phlebotomist will locate a suitable vein, typically in the antecubital fossa (the bend of the elbow).
• Aseptic Technique: The skin over the selected vein is thoroughly cleansed with an antiseptic swab (70% isopropyl alcohol) and allowed to air dry to prevent specimen contamination or infection.
• Sample Collection: A sterile, single-use needle is inserted into the vein. Multiple blood collection tubes (including EDTA tubes for HbA1c, gel barrier tubes for serum insulin, C-peptide, and autoantibodies, and fluoride tubes for fasting plasma glucose) are filled in a specific order of draw to prevent cross-contamination of additives.
• Post-Collection Care: Once the tubes are filled, the needle is gently removed, and immediate pressure is applied to the puncture site with a sterile cotton ball. A small adhesive bandage is applied to prevent bruising or minor bleeding.
• Duration and Experience: The entire venipuncture procedure takes less than five minutes. Patients may experience a mild, brief pinching sensation as the needle is inserted.
• Specimen Transport: The collected samples are immediately labeled with unique barcoded identifiers and transported under strict temperature-controlled conditions to the central testing facility of Chughtai Lab for high-throughput analysis.

When is a Getz Pharma Diabetes Subtypes Study Performed?

Atypical Presentation of Diabetes

Physicians frequently request this specialized study when a patient presents with atypical clinical features of diabetes that do not clearly align with standard Type 1 or Type 2 classifications. For example, young, non-obese individuals who present with progressive hyperglycemia but do not show signs of classic autoimmune destruction, or older adults who present with rapid beta-cell failure, require detailed subtyping. Identifying the precise metabolic profile helps avoid misdiagnosis and ensures the initiation of appropriate therapeutic regimens from the outset.

Suspected Autoimmune Diabetes in Adults (LADA)

Latent Autoimmune Diabetes in Adults (LADA) is a form of autoimmune diabetes that progresses much more slowly than classic Type 1 diabetes and is often initially misdiagnosed as Type 2 diabetes. Clinicians order this study to evaluate autoimmune markers, such as Glutamic Acid Decarboxylase Antibodies (GADA). Detecting these autoantibodies is crucial, as patients with LADA eventually experience complete beta-cell failure and require early insulin therapy, rather than long-term reliance on oral hypoglycemic agents that may exhaust remaining pancreatic function.

Evaluation of Insulin Resistance vs. Insulin Deficiency

Determining whether a patient’s primary pathological driver is severe insulin resistance or severe insulin deficiency is essential for targeted therapy. This study assesses fasting insulin and C-peptide levels alongside glucose to calculate indices of insulin resistance (such as HOMA-IR) and beta-cell function (HOMA-B). This differentiation allows endocrinologists to prescribe insulin-sensitizing medications (like metformin or pioglitazone) to highly resistant patients, while reserving insulin secretagogues or exogenous insulin for those with true insulin deficiency.

Poor Response to Standard Oral Hypoglycemic Agents

When diabetic patients fail to achieve optimal glycemic control despite being prescribed multiple standard oral anti-diabetic drugs, clinical subtyping is indicated. A poor therapeutic response often indicates that the underlying pathophysiological mechanism of the patient’s diabetes differs from what was assumed. By participating in this study, clinicians can identify if the patient belongs to a severe insulin-deficient or severe insulin-resistant cluster, allowing for a more rational, evidence-based adjustment of their pharmacological regimen.

Participation in Clinical Research and Precision Medicine

This study is performed as part of a collaborative clinical research initiative supported by Getz Pharma to map the unique phenotypic and genotypic characteristics of diabetes within the Pakistani population. Patients participating in this study contribute to a broader clinical database that helps researchers and healthcare policy makers understand regional variations in diabetes pathology, ultimately leading to the development of localized clinical guidelines and improved public health strategies.

What Does a Getz Pharma Diabetes Subtypes Study Detect?

The Getz Pharma (Diabetes Subtypes Study) at Chughtai Lab utilizes a comprehensive panel of biochemical, immunological, and metabolic assays to detect and evaluate several critical clinical parameters:

• Fasting Plasma Glucose (FPG): Measures the concentration of glucose in the blood after an overnight fast, serving as a primary indicator of basal glycemic status.
• Glycated Hemoglobin (HbA1c): Reflects the average blood glucose levels over the preceding 8 to 12 weeks, providing a reliable measure of long-term glycemic control.
• Fasting Serum Insulin: Evaluates the amount of active insulin circulating in the bloodstream, helping to distinguish between states of absolute insulin deficiency and hyperinsulinemia associated with resistance.
• C-Peptide Levels: Produced in an equal ratio to insulin, C-peptide serves as a highly stable and reliable marker of endogenous pancreatic beta-cell secretory capacity, particularly in patients receiving exogenous insulin therapy.
• Glutamic Acid Decarboxylase Antibodies (GADA): Detects the presence of autoimmune antibodies targeting pancreatic beta-cells, confirming an autoimmune etiology such as Type 1 diabetes or LADA.
• Homeostatic Model Assessment of Insulin Resistance (HOMA-IR): A calculated index derived from fasting glucose and insulin levels, quantifying the degree of peripheral insulin resistance.
• Homeostatic Model Assessment of Beta-Cell Function (HOMA-B): A calculated index that estimates the functional secretory capacity of the pancreatic beta-cells.
• Total Cholesterol: Measures the total amount of cholesterol in the blood, assessing overall cardiovascular risk.
• High-Density Lipoprotein (HDL) Cholesterol: Evaluates “good” cholesterol levels, which are often reduced in insulin-resistant states.
• Low-Density Lipoprotein (LDL) Cholesterol: Measures “bad” cholesterol, a key driver of atherogenesis in diabetic patients.
• Triglycerides: Elevated levels are a classic hallmark of diabetic dyslipidemia and insulin resistance.
• Serum Creatinine: Assesses baseline renal function, which is critical for determining the safety of various oral anti-diabetic medications.
• Estimated Glomerular Filtration Rate (eGFR): Provides a standardized calculation of kidney function to detect early diabetic nephropathy.
• Urinary Albumin-to-Creatinine Ratio (UACR): Detects microalbuminuria, the earliest clinical indicator of diabetic kidney disease.
• Alanine Aminotransferase (ALT): Evaluates liver function, helping to identify non-alcoholic fatty liver disease (NAFLD), which is highly prevalent in insulin-resistant diabetic subtypes.
• Aspartate Aminotransferase (AST): Assists in assessing hepatic metabolic health and cellular integrity.
• Body Mass Index (BMI) Correlation: Integrates physical anthropometric measurements with biochemical data to classify obesity-related diabetes subtypes.
• Systolic and Diastolic Blood Pressure: Correlates cardiovascular hemodynamics with metabolic clusters to evaluate metabolic syndrome.
• Severe Autoimmune Diabetes (SAID) Cluster: Characterized by early onset, low BMI, poor glycemic control, positive autoantibodies (GADA), and low insulin secretion.
• Severe Insulin-Deficient Diabetes (SIDD) Cluster: Characterized by GADA-negative status, low insulin secretion, high HbA1c, and an elevated risk of diabetic retinopathy.
• Severe Insulin-Resistant Diabetes (SIRD) Cluster: Characterized by severe insulin resistance, high BMI, and a significantly increased risk of diabetic nephropathy and fatty liver disease.
• Mild Obesity-Related Diabetes (MOD) Cluster: Characterized by moderate obesity, early onset, but a relatively mild clinical course with lower risk of microvascular complications.
• Mild Age-Related Diabetes (MARD) Cluster: Characterized by late-onset diabetes, mild metabolic disturbances, and a slowly progressive clinical course.

Turnaround Time and Report Access at Chughtai Lab

Chughtai Lab is committed to delivering highly accurate diagnostic reports with optimal efficiency. Due to the specialized nature of the Getz Pharma (Diabetes Subtypes Study), which involves complex immunological assays (such as GAD antibodies) and calculated metabolic indices, the processing time may vary. Typically, comprehensive results for this study are completed and verified within 3 to 5 working days from the time of sample collection.

Patients and referring physicians can access reports seamlessly through Chughtai Lab’s advanced digital infrastructure. Once the results are finalized and verified by a consultant pathologist, an automated SMS notification is sent to the patient’s registered mobile number. Reports can be downloaded directly from the official Chughtai Lab website using the secure patient portal, or accessed via the Chughtai Lab Mobile App. For added convenience, patients can also receive their diagnostic reports directly through WhatsApp or collect printed copies from any of Chughtai Lab’s numerous convenient collection centers located across Pakistan.

Diabetes Subtypes Study Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Fasting Plasma Glucose	70 – 99 mg/dL	≥ 126 mg/dL (Diagnostic of Diabetes Mellitus)
Glycated Hemoglobin (HbA1c)	< 5.7%	≥ 6.5% (Indicates Diabetes); > 8.0% (Poor Glycemic Control)
C-Peptide (Fasting)	1.1 – 4.4 ng/mL	< 0.5 ng/mL (Severe Insulin Deficiency); Elevated in Insulin Resistance
GAD Antibodies (GADA)	Negative (< 5.0 IU/mL)	Positive (Indicates Autoimmune Diabetes: Type 1 or LADA)
HOMA-IR Index	< 1.0 (Optimal Sensitivity)	> 1.9 (Early Resistance); > 2.9 (Severe Insulin Resistance)
HOMA-B Index	100% (Normal Beta-Cell Function)	Significantly reduced (Indicates progressive pancreatic beta-cell failure)
Fasting Serum Insulin	2.0 – 25.0 µIU/mL	< 2.0 µIU/mL (Deficiency); > 25.0 µIU/mL (Severe Hyperinsulinemia)
Triglycerides	< 150 mg/dL	Elevated (Common in Insulin-Resistant SIRD and MOD clusters)

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for Getz Pharma Diabetes Subtypes Study?

• Experienced Healthcare Professionals: Chughtai Lab features a highly qualified team of consultant pathologists, clinical biochemists, and laboratory technologists dedicated to diagnostic excellence.
• Patient-Focused Care: Every step of the diagnostic journey is designed with patient comfort, safety, and clear communication as top priorities.
• Quality Diagnostic Services: Operating under strict international quality control standards, Chughtai Lab ensures highly reproducible and clinically precise test results.
• Professional Reporting: Reports are meticulously reviewed, verified, and signed by board-certified pathologists to guarantee clinical accuracy.
• Modern Diagnostic Approach: Utilizing state-of-the-art automated analyzers and advanced immunological assay platforms for precise biomarker detection.
• Comfortable Environment: All collection centers are designed to provide a clean, hygienic, and welcoming environment for patients during sample collection.
• Convenient Location: With an extensive network of hundreds of collection centers across Pakistan, accessing high-quality diagnostic care is highly convenient.
• Commitment to Accurate Diagnosis: Partnering in major clinical research initiatives like the Getz Pharma Study reflects Chughtai Lab’s dedication to advancing precision medicine in Pakistan.